U.S., July 10 -- ClinicalTrials.gov registry received information related to the study (NCT07056517) titled 'Pharmacokinetics and Safety of M107 Orally Disintegrating Tablet in Healthy Adults' on June 30.
Brief Summary: Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of lobeglitazone administered as M107 Orally Disintegrating Tablet and Duvie tablet in healthy adult participants under fasted and fed conditions.
Study Start Date: July 08
Study Type: INTERVENTIONAL
Condition:
Healthy
Intervention:
DRUG: M107 and Duvie - Cohort 1
Dosage form - Oral tablets Dosage - Duvie 0.415 mg and M107 ODT 0.4 mg Participants will receive each treatment once under fasted conditions in a randomized two-period crossover design....